The healthcare services firm raised its earnings outlook as VITAS posts higher revenue growth and EBITDA margins.
Chemed Corporation updated its Q2 2026 earnings per share guidance to $25-$25.75, citing stronger-than-expected performance from its VITAS segment. The company highlighted revenue growth and EBITDA margin expansion as key drivers behind the revised forecast.
VITAS, Chemed’s hospice care unit, targeted average daily census (ADC) growth of 5.75%-6.25%, exceeding prior expectations. The segment’s outperformance provided additional cushion to the company’s financial outlook, management noted during the earnings call.
The updated guidance reflects improved operational efficiency and demand trends in the hospice care market. Chemed did not disclose immediate market reactions to the announcement.